The regulatory and research present

The short version

BPC-157 is a synthetic 15-amino-acid peptide first studied for its ability to protect the stomach lining. Thirty years of animal research have since shown it influences healing in tendons, ligaments, muscle, bone, gut, spinal cord, and cardiac tissue — all through a common mechanism involving the growth of new blood vessels (called angiogenesis) and a nitric oxide signaling cascade.

As of mid-2026, BPC-157 has no FDA approval, no approved human dose, and is prohibited in competitive sport by WADA. Only three small, uncontrolled human studies exist. The compound is under active regulatory review — the FDA's compounding advisory committee is scheduled to evaluate it in July 2026.

This site covers both panels: the preclinical research record and the regulatory present. For what research-use communities say about the experience of using it, see the effects page.

What is BPC-157?

BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide with the sequence GEPPPGKPADDAGLV and a molecular weight of 1,419.54 Da. It was derived from a protein isolated from human gastric juice — not extracted from it — and is produced today by solid-phase peptide synthesis (SPPS). The compound also carries several research designations: PL 14736, PLD-116, and stable gastric pentadecapeptide BPC 157 ^[16].

The gastric origin matters mechanistically. BPC-157 is unusually stable in gastric juice for more than 24 hours — a property that distinguishes it from most peptides, which would be cleaved rapidly by stomach acid, and that is central to the compound's demonstrated oral activity in preclinical models ^[20].

Research-grade BPC-157 is typically supplied as a lyophilized acetate salt, specified at ≥98% purity by reverse-phase HPLC with ESI-MS identity confirmation. The compound exists in two salt forms — free base and acetate — and both have appeared in the regulatory literature. The FDA's July 2026 PCAC review is evaluating both forms separately for potential inclusion on the 503A Bulks List.

The name 'Body Protection Compound' predates any clinical designation. It was assigned during early gastroprotection studies, when the peptide's cytoprotective effects on the gastric mucosa were its defining property ^[21]. Subsequent decades of research expanded the picture considerably.

What does three decades of preclinical research show?

The BPC-157 literature is substantial, largely concentrated in rodent models, and weighted heavily toward a single Croatian research group (Sikiric, Seiwerth, and collaborators at the University of Zagreb). Both the breadth and the concentration are worth noting plainly.

In musculoskeletal models, BPC-157 at 10 μg/kg intraperitoneal significantly improved Achilles tendon healing biomechanics — load-to-failure, stiffness, and Young's elasticity modulus — in rats with Achilles detachment. The same study showed the compound counteracted methylprednisolone-associated healing impairment ^[1]. A separate model of transected Achilles tendon confirmed accelerated healing and dose-dependent improvements in tendocyte growth in vitro ^[2].

In gastrointestinal models, BPC-157 at 400–800 ng/kg intramuscular reduced gastric ulcer area by 45–65% across three ulcer models in rats, outperforming famotidine at equivalent doses ^[8]. Colonic ischemia studies showed the peptide restored blood supply and mucosal folds within 15 minutes of topical application at 10 μg/kg ^[7].

Neural and cardiac findings extend the picture further. At 10 μg/kg intraperitoneal, administered 10 minutes post-injury, BPC-157 produced clinical improvement and motor function recovery through 360 days of follow-up in rats with spinal cord compression ^[10]. In an isoprenaline-induced myocardial infarction model, 10 ng/kg and 10 μg/kg intraperitoneal reduced cardiac enzyme markers and preserved left ventricular function ^[12].

A 2021 wound-healing review found that BPC-157 upregulated 19 wound-healing genes — including Akt1, Vegfa, Nos3, and several Mapk variants — within minutes to hours post-injury, and demonstrated efficacy across six distinct wound and injury model types in rats ^[15].

The consistent thread across all of these models is the same set of molecular targets: VEGFR2 upregulation, Akt-eNOS axis activation, and the downstream nitric oxide synthesis and angiogenesis that follows. A 2025 narrative review from McGuire and colleagues characterized this mechanism as the primary effector arm and noted no adverse effects across three published human studies ^[16].

What is the regulatory status as of mid-2026?

The regulatory present is active and unresolved. BPC-157 has no FDA approval for any human indication, no IND (Investigational New Drug) application on file in the United States, and no USP/NF monograph.

In September 2023, the FDA placed BPC-157 on the 503A Category 2 list — effectively prohibiting compounding pharmacies operating under Section 503A of the FDCA from producing it. In April 2026, the FDA removed BPC-157 (along with TB-500) from Category 2 following withdrawal of their nominations. Neither compound was placed on Category 1 (the permitted 503A Bulks List). The April 2026 removal created a regulatory gray zone: not explicitly prohibited, not authorized.

The FDA Pharmacy Compounding Advisory Committee (PCAC) is scheduled to formally review BPC-157 free base and BPC-157 acetate in July 2026, with ulcerative colitis as the nominated use case. The outcome of that review will determine whether either form moves to the 503A Bulks List.

In parallel, WADA (the World Anti-Doping Agency) has prohibited BPC-157 under Section S0 — Non-Approved Substances — since 2022. Athletes in WADA-governed competition cannot use BPC-157 regardless of route or stated purpose.

For researchers: BPC-157 is classified as a research chemical and is not approved for human consumption by the FDA or any major regulatory agency.

What human data exists?

Three small published human studies exist as of 2025. Their findings are notable; their scale is not.

The most recent is a 2024 pilot study in 12 patients with moderate-to-severe interstitial cystitis (IC) who had failed pentosan polysulfate — the only FDA-approved IC therapy. Intravesicular BPC-157 injections produced 80–100% symptom resolution at six weeks in all 12 patients ^[18]. This is a striking outcome in a refractory population, and it represents the first published human data on intravesicular BPC-157.

Before that, a knee pain pilot study reported significant pain relief in 14 of 16 patients via intra-articular injection, and a two-subject IV safety study documented tolerance of up to 20 mg intravenous without adverse events ^[16].

A 2025 narrative review from McGuire and colleagues synthesized all three studies and concluded BPC-157 should be considered investigational pending controlled human trials — a characterization that is both accurate and deliberately cautious ^[16]. No randomized controlled trials have been published. A Phase 2 IBD trial (PL 14736, oral) was conducted by Pliva in Croatia but peer-reviewed results were never published — a gap that the clinical and regulatory literature frequently cites.

What this site is

BPC-157 Meds is an independent editorial project that publishes summaries of the peer-reviewed research literature on BPC-157 (Body Protection Compound 157). The site is organized around a two-panel editorial frame: the literature on one side, the regulatory and compounding present on the other.

This site is not affiliated with any vendor, compounding pharmacy, or manufacturer. It does not provide medical advice and does not employ clinicians. The modifier 'meds' in the domain name is editorial framing — a statement about the regulatory context the compound currently occupies, not a service the site offers.

All content is editorial commentary on publicly available science. Citations are drawn from PubMed, PMC, Frontiers in Pharmacology, and peer-reviewed journals. A complete reference list with DOIs and PubMed URLs is available on the References page.